Northview Congratulates Neovasc Inc. on US $100M Transaction with Shockwave Medical

Northview would like to congratulate Neovasc Inc. on their approximately US $100 million transaction with Shockwave Medical.

Neovasc is a minimally invasive cardiac device company focusing on the treatment of refractory angina. Their patented device, the Reducer, is CE marked and approved for use in the EU and currently has a multicenter study underway in the US (COSIRA II).

The acquisition deal with Shockwave Medical Inc. will result in the purchase of outstanding common shares as well as an agreement for future regulatory milestone payments.

“We have been long term investors, past consultants, and members of the Board of Directors of Neovasc and are very proud of what the Company and team has accomplished” said Doug Janzen, CEO of Northview Lifesciences.

Congratulations to the entire team at Neovasc.

The official Neovasc press release can be accessed via the link provided: https://neovasc.com/newsreleases/shockwave-medical-to-acquire-neovasc/

Original source here.